Primaquine: Difference between revisions
ClaireLewis (talk | contribs) |
ClaireLewis (talk | contribs) No edit summary |
||
| (One intermediate revision by one other user not shown) | |||
| Line 1: | Line 1: | ||
==Administration== | ==Administration== | ||
*Type: | *Type: [[Antimalarial]], anti-[[PCP]] | ||
*Dosage Forms: | *Dosage Forms: | ||
*Routes of Administration: oral | *Routes of Administration: oral | ||
| Line 6: | Line 6: | ||
==Adult Dosing== | ==Adult Dosing== | ||
* [[PCP pneumonia]], HIV+ : 15-30mg PO daily with clindamycin | *[[PCP pneumonia]], HIV+ : 15-30mg PO daily with clindamycin | ||
*[[Malaria]] treatment: 26.3-52.6mg PO daily in combination with an additional anti-malarial agent | *[[Malaria]] treatment: 26.3-52.6mg PO daily in combination with an additional anti-malarial agent | ||
*[[Malaria]] prophylaxis: 52.6mg PO daily starting 1-2 days prior to arrival in endemic area until 7-14 days after departure | *[[Malaria]] prophylaxis: 52.6mg PO daily starting 1-2 days prior to arrival in endemic area until 7-14 days after departure | ||
| Line 48: | Line 48: | ||
<references/> | <references/> | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
[[Category:ID]] | |||
Latest revision as of 21:57, 23 September 2019
Administration
- Type: Antimalarial, anti-PCP
- Dosage Forms:
- Routes of Administration: oral
- Common Trade Names:
Adult Dosing
- PCP pneumonia, HIV+ : 15-30mg PO daily with clindamycin
- Malaria treatment: 26.3-52.6mg PO daily in combination with an additional anti-malarial agent
- Malaria prophylaxis: 52.6mg PO daily starting 1-2 days prior to arrival in endemic area until 7-14 days after departure
Pediatric Dosing
- Malaria treatment: 0.8 mg/kg PO daily (max 52.6mg daily) in combination with an additional anti-malarial agent
- Malaria prophylaxis: 0.8 mg/kg PO daily (max 52.6mg daily) starting 1-2 days prior to arrival in endemic area until 7-14 days after departure
Special Populations
- Pregnancy Rating: D
- Lactation risk: Infant risk cannot be ruled out
- Renal dosing:
- Hepatic dosing:
Contraindications
- Allergy to class/drug
- Concomitant use with other potentially hemolytic or myeloid suppressing drugs
- Acutely ill patients with diseases prone to granulocytopenia (e.g. SLE or rheumatoid arthritis)
Adverse Reactions
Serious
- Hemolytic anemia, leukopenia
- Methemoglobinemia
Common
- Nausea, abdominal pain
Pharmacology
- Half-life: 4-7 hours
- Metabolism:
- Excretion:
Mechanism of Action
- Eliminates tissue infection, thus preventing erythrocytic forms of parasite